HSBC downgrades Eli Lilly, says shares are ‘priced to perfection' [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
have become overly optimistic and that the company's shares now look “priced to perfection.” The call, led by HSBC analyst Rajesh Kumar, saw the bank cut LLY's price target to $850 from $1,070. HSBC believes the broader Healthcare sector is positioned to outperform in the coming quarter, but warned that “elevated multiples and crowded positioning in the sector remains a key risk.” Within that backdrop, the bank now sees the risk-reward balance for Lilly as unfavourable because “obesity TAM expectations seem inflated.” The downgrade hinges on three concerns. First, HSBC said it thinks the market's total addressable market expectations for obesity drugs “remains elevated (USD150bn),” while its own estimate sits at $80-120bn by 2032. The bank also expects price competition to intensify, noting that upcoming price cuts in 2026 will challenge assumptions embedded in Lilly's guidance. Second, HSBC warned that expectations for Lilly's oral drug launch are too high. The analysts w
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: The Illusion Of Cheap [Seeking Alpha]Seeking Alpha
- This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock [Yahoo! Finance]Yahoo! Finance
- Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S Investigated by the Portnoy Law FirmGlobeNewswire
- Novo Nordisk: Buy Hand Over Fist While Others Panic [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/17/26 - Form 6-K
- 3/9/26 - Form 6-K
- 3/2/26 - Form 6-K
- NVO's page on the SEC website